Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo
Financial Modeling Prep is a new concept that informs you about stock markets information (news, currencies and stock prices).
We always strive to give you the best and most updated information. We also gives you free financial modeling methodology
through our academy. Most investment banking firms follow our guidelines to get discounted cash flow statement of companies to
see if they are undervalued, overvalued or simply at par value. You can find all financial models and valuation techniques
that is used in corporate finance to get companies intrinsic valuation. Most private equity firm use financial modeling for
decision making when it comes to hold, buy or sell a particular stock.